188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: Preclinical assessment

Journal of Nuclear Medicine

Volumn 55, Issue 11, 2014, Pages 1842-1848

  Altai, Mohamed ^a   Wallberg, Helena ^b   Honarvar, Hadis ^a   Strand, Joanna ^a   Orlova, Anna ^a   Varasteh, Zohreh ^a   Sandström, Mattias ^a,c   Löfblom, John ^b   Larsson, Erik ^d   Strand, Sven Erik ^d   Lubberink, Mark ^a,c   Stah, Stefan ^a,b   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

188Re; Affibody molecule; Dosimetry; HER2

Indexed keywords

AFFIBODY MOLECULE; C TERMINAL GLYCYLGLYCYLCYSTEINE PEPTIDE BASED CHELATOR RE 188; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCONIC ACID; RADIOPHARMACEUTICAL AGENT; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; CHELATING AGENT; ERBB2 PROTEIN, HUMAN; GLYCYL-GLYCYL-CYSTEINE; OLIGOPEPTIDE; PEPTIDE; RADIOISOTOPE; RHENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE MARROW; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOSIMETRY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SCREENING; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2 EXPRESSING TUMOR; ISOTOPE LABELING; KIDNEY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; RADIATION DOSE; RADIATION INJURY; RADIOACTIVITY; RADIOISOTOPE THERAPY; SCINTILLATION CAMERA; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; HUMAN; METABOLISM; MOUSE; OVARIAN NEOPLASMS; RADIOMETRY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CHELATING AGENTS; DRUG EVALUATION, PRECLINICAL; FEMALE; GLUCONATES; HUMANS; MICE; MICE, NUDE; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PEPTIDES; RADIATION DOSAGE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RHENIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910602926     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.140194     Document Type: Article

References (34)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
3. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
4. Diéras V, Bachelot T. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. Target Oncol. July 14, 2013 [Epub ahead of print].
5. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl 1):115S-127S.
6. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv. 2006;3:53-70.
7. Pouget JP, Navarro-Teulon I, Bardiés M, et al. Clinical radioimmunotherapy: the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720-734.
8. Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids. 2011;41:1037-1047.
9. Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008;275:2668-2676.
10. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res. 2006;66:4339-4348.
11. Feldwisch J, Tolmachev V. Engineering of Affibody molecules for therapy and diagnostics. Methods Mol Biol. 2012;899:103-126.
12. Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled Affibody molecules. J Nucl Med. 2010;51:892-897.
13. Sörensen J, Sandberg D, Sandström M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 Affibody molecule. J Nucl Med. 2014;55:730-735.
14. Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A. In vivo and in vitro studies on renal uptake of radiolabeled Affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm. 2013;28:187-195.
15. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435-442.
16. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging. 2009;36:692-701.
17. Engfeldt T, Tran T, Orlova A, Widström C, Karlström AE, Tolmachev V. 99mTcchelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging. 2007;34:1843-1853.
18. Tran T, Engfeldt T, Orlova A, et al. 99mTc-maEEE-ZHER2:342, an Affibody moleculebased tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem. 2007;18:1956-1964.
19. Tran TA, Ekblad T, Orlova A, et al. Effects of lysine-containing mercaptoacetylbased chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem. 2008;19:2568-2576.
20. Ekblad T, Tran T, Orlova A, et al. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245-2255.
21. Ahlgren S, Wållberg H, Tran TA, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med. 2009;50:781-789.
22. Wållberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant Affibody molecules improves their biodistribution and imaging properties. J Nucl Med. 2011;52:461-469.
23. Altai M, Wållberg H, Orlova A, et al. Order of amino acids in C-terminal cysteinecontaining peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids. 2012;42:1975-1985.
24. Cyr JE, Pearson DA, Wilson DM, et al. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186: chemistry and initial biological studies. J Med Chem. 2007;50:1354-1364.
25. Orlova A, Tran TA, Ekblad T, Karlström AE, Tolmachev V. 186Re-maGSG-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging. 2010;37:260-269.
26. Wållberg H, Löfdal PÅ , Tschapalda K. Affinity recovery of eight HER2-binding Affibody variants using an anti-idiotypic Affibody molecule as capture ligand. Protein Expr Purif. 2011;76:127-135.
27. Larsson E, Strand SE, Ljungberg M, Jönsson BA. Mouse S-factors based on Monte Carlo simulations in the anatomical realistic Moby phantom for internal dosimetry. Cancer Biother Radiopharm. 2007;22:438-442.
28. Larsson E, Ljungberg M, Strand SE, Jönsson BA. Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for preclinical dosimetry studies. Acta Oncol. 2011;50:973-980.
29. Stabin MG. Fundamentals of Nuclear Medicine Dosimetry. New York, NY: Springer; 2008:83-86.
30. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
31. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.
32. Arora P, Oas TG, Myers JK. Fast and faster: a designed variant of the B domain of protein A folds in 3 microsec. Protein Sci. 2004;13:847-853.
33. Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138-1146.
34. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78-88.